BSH are sharing this message from the Medicines and Healthcare products Regulatory Agency:
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 2 Medicines Recall of a specific batch of Mercaptopurine 50mg tablets as a precautionary measure, due to microbial contamination following a small number of complaints of discoloured tablets within the packs, identified when the packs have been opened by healthcare professionals.
Mercaptopurine is a medication used for the treatment of acute leukaemia in adults, adolescents and children. It can also be used to treat ulcerative colitis and Crohn’s disease, although use for these conditions is unlicensed.
Healthcare professionals are asked to quarantine a...
1 day ago